Data Byte: BMS TYK2 inhibitor could set bar for oral efficacy in psoriasis

With Bristol Myers’ TYK2 inhibitor beating blockbuster psoriasis drug Otezla in a Phase III trial, the next question is how the oral therapy’s efficacy stacks up to that of injectable mAbs. 

Bristol Myers Squibb Co. (NYSE:BMY) said Tuesday that deucravacitinib (BMS-986165) met the primary and secondary endpoints in the Phase III POETYK PSO-1 trial in moderate to severe psoriasis patients, showing a statistically significant improvement vs. PDE-4 inhibitor Otezla apremilast on the co-primary endpoints of PASI-75 response and the proportion of patients achieving 0 or 1 on the static Physician’s Global Assessment (sPGA 0/1) at week 16...